SEPTInvestingStart Free

DTIL 8-K: Fda approval

Precision BioSciences

Filed with the SEC on · accession 0001628280-26-070542

DTIL filed a 8-K (current report) with the SEC on Nov 5, 2026. Precision BioSciences announced positive Phase 1 data for PBGENE-HBV in chronic hepatitis B, showing undetectable pgRNA in 100% of evaluable patients at the 0.4 mg/kg dose, and the program is advancing to Phase 2. The stock moved +21.6% by the first close after the filing.

Summary of the filing

Precision BioSciences announced positive Phase 1 data for PBGENE-HBV in chronic hepatitis B, showing undetectable pgRNA in 100% of evaluable patients at the 0.4 mg/kg dose, and the program is advancing to Phase 2. The company also reported that the first DMD patient completed the eight-week observation period with no safety concerns, and the DSMB endorsed proceeding with additional dosing.

For details, click here →How to read a 8-K →

Key details

IssuerPrecision BioSciences, Inc.

How DTIL stock reacted

Close before

$8.12

Nov 4, 2026

First close after

+21.55%

$9.87

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for DTIL, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for DTIL?

Click here

Frequently asked questions

What did DTIL file with the SEC on Nov 5, 2026?

DTIL filed a 8-K (Fda approval). Precision BioSciences announced positive Phase 1 data for PBGENE-HBV in chronic hepatitis B, showing undetectable pgRNA in 100% of evaluable patients at the 0.4 mg/kg dose, and the program is advancing to Phase 2. The company also reported that the first DMD patient completed the eight-week observation period with no safety concerns, and the DSMB endorsed proceeding with additional dosing.

What does a fda approval mean for DTIL stock?

For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did DTIL stock react to this filing?

DTIL closed at $8.12 before the filing and $9.87 on Nov 5, 2026 (+21.55%).

Other DTIL SEC filings

Get alerts when DTIL files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
DTIL overviewDTIL analysisDTIL newsLatest SEC filings